Acuitas Therapeutics President & CEO Named as a Pacific Winner in the EY Entrepreneur of the Year Award Program
In recognition of his commitment to innovation and entrepreneurial spirit, Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, has been named as one of seven Pacific winners in the EY Entrepreneur of the Year Award Program. He and the other Pacific award winners will go on to compete for 10 national titles and the overall top spot in Canada at the EY virtual celebration in November 2022. You can learn more about Dr. Madden and the other Pacific award winners here: https://go.ey.com/3ANnLEo.
“The life sciences sector in B.C. and across Canada is built on an entrepreneurial foundation and I am honoured to have been recognized as a Pacific winner in the EY award program,” said Dr. Madden. “It is important to highlight that no entrepreneur achieves anything on their own, and I think that this is especially true in the life sciences sector. In accepting this award, I want to acknowledge the Acuitas team. We are a collaborative, cooperative and connected group of scientists, administrators, business development, finance, legal and communications professionals, and I am incredibly proud of the work that we do together.” He added: “We are excited to move to the national level of this award program and I look forward to celebrating with my friends and colleagues at Acuitas.”
About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious diseases.